May 2007
Volume 48, Issue 13
ARVO Annual Meeting Abstract  |   May 2007
Pegaptanib and Intravitreal Moxifloxacin in Neovascular Age-related Macular Degeneration: A Case Series
Author Affiliations & Notes
  • M. D. Bennett
    Retina Institute of Hawaii, Honolulu, Hawaii
  • W. Yee
    Retina Institute of Hawaii, Honolulu, Hawaii
  • Footnotes
    Commercial Relationships M.D. Bennett, Eyetech, Genentech, C; Eyetech, Genentech, R; W. Yee, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 4530. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. D. Bennett, W. Yee; Pegaptanib and Intravitreal Moxifloxacin in Neovascular Age-related Macular Degeneration: A Case Series. Invest. Ophthalmol. Vis. Sci. 2007;48(13):4530.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose:: To evaluate the effectiveness and safety of pegaptanib combined with moxifloxacin for the treatment of patients with neovascular age-related macular degeneration (AMD).

Methods:: Patients ≥50 years of age with all sizes and angiographic subtypes of subfoveal choroidal neovascularization secondary to AMD, and best-corrected visual acuities (BCVAs) of 20/40 to 20/800 were eligible. Active untreated lesions and lesions previously treated with photodynamic therapy or intravitreous or subtenon kenalog were eligible. Patients received combination treatment of pegaptanib 0.3mg with 135µg/0.1 mL moxifloxacin every 6 weeks for the first six months and subsequently the patients received only pegaptanib. Before injection and 4-5 days post-injection, BCVA was assessed with ETDRS charts. The primary endpoint was the percentage of eyes losing <15 letters from baseline to month 12; secondary endpoints at month 12 were percentages of eyes with stable or improved vision and with gains of ≥15 letters, and mean change in BCVA.

Results:: Twelve-month follow-up has been completed for 70 eyes (14 with no previous treatment) of 66 patients. Loss of <15 letters from baseline to week 12 was seen in 68/70 (97.1%) eyes overall, including 14/14 (100%) with de novo lesions and 54/56 (96.4%) previously treated eyes. Stable or improved vision was seen in 55/70 (78.6%), 11/14 (78.6%), and 44/56 (78.6%) eyes, respectively, and gains of ≥15 letters were noted in 14/70 (20.0%), 4/14 (28.6%), and 10/56 (17.9%) eyes, respectively. At month 12, BCVA improved by a mean of 5.4 letters overall and by 9.21 letters in de novo patients. Adverse events were mild and related to the injection procedure; endophthalmitis was not observed in any patient.

Conclusions:: Pegaptanib combined with moxifloxacin appears to be effective and safe in treating neovascular AMD.

Keywords: age-related macular degeneration • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • antibiotics/antifungals/antiparasitics 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.